{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:57:37Z","timestamp":1785275857071,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11596-025-00030-6","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T11:05:46Z","timestamp":1743159946000},"page":"301-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Toxicities Associated with Sacituzumab Govitecan: Data from Clinical Trials and a Real-World Pharmacovigilance Database"],"prefix":"10.1007","volume":"45","author":[{"given":"Qiao-yun","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-ping","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-ge","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-ka","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8632-518X","authenticated-orcid":false,"given":"Jing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"2","key":"30_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165\u2013182.","journal-title":"CA Cancer J Clin."},{"key":"30_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107917","volume":"229","author":"Y Jin","year":"2022","unstructured":"Jin Y, Schladetsch MA, Huang X, et al. Stepping Forward in Antibody-drug Conjugate Development. Pharmacol Ther. 2022;229:107917.","journal-title":"Pharmacol Ther."},{"issue":"2","key":"30_CR3","first-page":"108","volume":"18","author":"MS Sheikh","year":"2023","unstructured":"Sheikh MS, Huang Y. Antibody-drug Conjugates for Breast Cancer Treatment.Recent Pat Anti-Canc. 2023;18(2):108\u2013113.","journal-title":"Recent Pat Anti-Canc."},{"issue":"1","key":"30_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","volume":"14","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14(1):20.","journal-title":"J Hematol Oncol."},{"key":"30_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1476-4598-9-253","volume":"9","author":"R Cubas","year":"2010","unstructured":"Cubas R, Zhang S, Li M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253","journal-title":"Mol Cancer."},{"issue":"8","key":"30_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","volume":"20","author":"DM Goldenberg","year":"2020","unstructured":"Goldenberg DM, Sharkey RM. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. Expert Opin Biol Th. 2020;20(8):871\u2013885.","journal-title":"Expert Opin Biol Th."},{"issue":"7","key":"30_CR7","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","volume":"27","author":"S Wahby","year":"2021","unstructured":"Wahby S, Fashoyin-Aje L, Osgood CL, et al. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. Clin Cancer Res. 2021;27(7):1850\u20131854.","journal-title":"Clin Cancer Res."},{"issue":"16","key":"30_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529\u20131541.","journal-title":"N Engl J Med."},{"issue":"4","key":"30_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","volume":"35","author":"Y Loriot","year":"2024","unstructured":"Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, et al. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Ann Oncol. 2024;35(4):392\u2013401.","journal-title":"Ann Oncol."},{"issue":"29","key":"30_CR10","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, et al. Sacituzumab Govitecan in Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer. J Clin Oncol. 2022;40(29):3365\u20133376.","journal-title":"J Clin Oncol."},{"issue":"24","key":"30_CR11","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","volume":"35","author":"RS Heist","year":"2017","unstructured":"Heist RS, Guarino MJ, Masters G, et al. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017;35(24):2790\u20132797.","journal-title":"J Clin Oncol."},{"issue":"19","key":"30_CR12","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","volume":"23","author":"JE Gray","year":"2017","unstructured":"Gray JE, Heist RS, Starodub AN, et al. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I\u2013inhibiting Antibody\u2013Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res. 2017;23(19):5711\u20135719.","journal-title":"Sacituzumab Govitecan. Clin Cancer Res."},{"key":"30_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Therapeut. 2019;200:110\u2013125.","journal-title":"Pharmacol Therapeut."},{"issue":"4","key":"30_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/ebmed-2016-110401","volume":"21","author":"MH Murad","year":"2016","unstructured":"Murad MH, Asi N, Alsawas M, et al. New evidence pyramid. Evid Based Med. 2016;21(4):125\u2013127.","journal-title":"Evid Based Med."},{"issue":"6","key":"30_CR15","first-page":"340","volume":"43","author":"CL Ventola","year":"2018","unstructured":"Ventola CL. Big Data and Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions. Pharmacol Ther. 2018;43(6):340\u2013351.","journal-title":"Pharmacol Ther."},{"issue":"7","key":"30_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess S, Butterworth A, Thompson SG. Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data. Genet Epidemiol. 2013;37(7):658\u2013665.","journal-title":"Genet Epidemiol."},{"issue":"2","key":"30_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","volume":"30","author":"R B\u00f6hm","year":"2012","unstructured":"B\u00f6hm R, H\u00f6cker J, Cascorbi I, et al. OpenVigil\u2014free eyeballs on AERS pharmacovigilance data. Nat Biotechnol. 2012;30(2):137\u2013138.","journal-title":"Nat Biotechnol."},{"issue":"8","key":"30_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40264-018-0661-3","volume":"41","author":"E Raschi","year":"2018","unstructured":"Raschi E, Girardi A, Poluzzi E, et al. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems. Drug Saf. 2018;41(8):745\u2013752.","journal-title":"Drug Saf."},{"issue":"12","key":"30_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u20131589.","journal-title":"Lancet Oncol."},{"issue":"D1","key":"30_CR20","doi-asserted-by":"publisher","first-page":"D1200","DOI":"10.1093\/nar\/gkab880","volume":"50","author":"G Xiong","year":"2022","unstructured":"Xiong G, Yang Z, Yi J, et al. DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2022;50(D1):D1200\u2013D1207.","journal-title":"Nucleic Acids Res."},{"key":"30_CR21","unstructured":"Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center. Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition). Zhonghua Zhong Liu Za Zhi (Chinese). 2023;45(9):741\u2013762."},{"key":"30_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110407","volume":"129","author":"F Liu","year":"2020","unstructured":"Liu F, Ke J, Song Y. T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives. Biomed Pharmacother. 2020;129:110407.","journal-title":"Biomed Pharmacother."},{"issue":"6","key":"30_CR23","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","volume":"107","author":"DJ Kuter","year":"2022","unstructured":"Kuter DJ. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematol J. 2022;107(6):1243\u20131263.","journal-title":"Haematol J."},{"issue":"10","key":"30_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab Govitecan: First Approval. Drugs. 2020;80(10):1019\u20131025.","journal-title":"Drugs."},{"issue":"11","key":"30_CR25","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2014;370(11):997\u20131007.","journal-title":"N Engl J Med."},{"issue":"1","key":"30_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000522068","volume":"17","author":"D L\u00fcftner","year":"2022","unstructured":"L\u00fcftner D, Fasching PA, Haidinger R, et al. ABC6 Consensus: Assessment by a Group of German Experts. Breast Care (Basel). 2022;17(1):90\u2013100.","journal-title":"Breast Care (Basel)."},{"issue":"5","key":"30_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","volume":"66","author":"V Bergqvist","year":"2017","unstructured":"Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66(5):581\u2013592.","journal-title":"Cancer Immunol Immunother."},{"key":"30_CR28","doi-asserted-by":"publisher","first-page":"175628481988419","DOI":"10.1177\/1756284819884196","volume":"12","author":"UN Shivaji","year":"2019","unstructured":"Shivaji UN, Jeffery L, Gui X, et al. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol. 2019;12:1756284819884196.","journal-title":"Therap Adv Gastroenterol."},{"key":"30_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s10637-016-0336-9","volume":"34","author":"MH Shah","year":"2016","unstructured":"Shah MH, Lorigan P, O\u2019Brien MER, et al. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Invest New Drugs. 2016;34:290\u2013299.","journal-title":"Invest New Drugs."},{"issue":"10","key":"30_CR30","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1245\/s10434-017-5982-4","volume":"24","author":"SA McLaughlin","year":"2017","unstructured":"McLaughlin SA, Staley AC, Vicini F, et al. Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel. Ann Surg Oncol. 2017;24(10):2818\u20132826.","journal-title":"Ann Surg Oncol."},{"issue":"20","key":"30_CR31","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMcp1803290","volume":"379","author":"SG Rockson","year":"2018","unstructured":"Rockson SG. Lymphedema after Breast Cancer Treatment. N Engl J Med. 2018;379(20):1937\u20131944.","journal-title":"N Engl J Med."},{"issue":"10","key":"30_CR32","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","volume":"33","author":"IE Krop","year":"2015","unstructured":"Krop IE, Suter TM, Dang CT, et al. Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2\u2013Positive Early-Stage Breast Cancer. J Clin Oncol. 2015;33(10):1136\u20131142.","journal-title":"J Clin Oncol."},{"issue":"21","key":"30_CR33","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","volume":"28","author":"M Procter","year":"2010","unstructured":"Procter M, Suter TM, de Azambuja E, et al. Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. J Clin Oncol. 2010;28(21):3422\u20133428.","journal-title":"J Clin Oncol."},{"issue":"6","key":"30_CR34","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/annonc\/mdy533","volume":"30","author":"D Lenihan","year":"2019","unstructured":"Lenihan D, Suter T, Brammer M, et al. Corrections to \u201cPooled analysis of cardiac safety in patients with cancer treated with pertuzumab.\u201d Ann Oncol. 2019;30(6):1021.","journal-title":"Ann Oncol."},{"key":"30_CR35","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975.","journal-title":"Front Immunol."},{"key":"30_CR36","doi-asserted-by":"publisher","first-page":"23262","DOI":"10.1038\/srep23262","volume":"6","author":"K Shen","year":"2016","unstructured":"Shen K, Ma X, Zhu C, et al. Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer: a Meta-analysis. Sci Rep. 2016;6:23262.","journal-title":"Sci Rep."},{"issue":"8","key":"30_CR37","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.clbc.2023.09.005","volume":"23","author":"GP Dowling","year":"2023","unstructured":"Dowling GP, Daly GR, Keelan S, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer: A Systematic Review and Meta-Analysis. Clin Breast Cancer. 2023;23(8):847\u2013855.","journal-title":"Clin Breast Cancer."},{"issue":"25","key":"30_CR38","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","volume":"41","author":"PH O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023;41(25):4107\u20134117.","journal-title":"J Clin Oncol."},{"key":"30_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","volume":"53","author":"S Zsch\u00e4bitz","year":"2023","unstructured":"Zsch\u00e4bitz S, Biernath N, Hilser T, et al. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort. Eur Urol Open Sci. 2023;53:31\u201337.","journal-title":"Eur Urol Open Sci."},{"key":"30_CR40","doi-asserted-by":"crossref","unstructured":"Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746\u2013756.","DOI":"10.1016\/j.annonc.2021.03.005"},{"key":"30_CR41","doi-asserted-by":"crossref","unstructured":"Yap TA, Hamilton E, Bauer T, et al. Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO Precis Oncol. 2022;6:e2100456.","DOI":"10.1200\/PO.21.00456"},{"key":"30_CR42","doi-asserted-by":"crossref","unstructured":"Marm\u00e9 F, Hanusch C, Furlanetto J, et al. 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. Ann Oncol. 2022;33:S148\u2013S149.","DOI":"10.1016\/j.annonc.2022.03.074"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00030-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-025-00030-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00030-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T19:03:08Z","timestamp":1746471788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-025-00030-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["30"],"URL":"https:\/\/doi.org\/10.1007\/s11596-025-00030-6","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"19 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare no competing interests. Figure\u00a0 is created by Figdraw ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All analyses were based on previous published studies or public databases, thus no ethical approval and patient consent are required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}